Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| QUEST DIAGNOSTICS INCDGX · Entity 2118 | SVP & General Counsel | August 28, 2026 | August 31, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
QUEST DIAGNOSTICS INC
Report date August 28, 2026 · Filed August 31, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 36,557 |
Ending reported balance
After 2026-08-28 transaction · row 5
5 source rows · reconciled sequenceRow 1 · 2026-08-28 · Exercise / conversion · Acquired 22,677 · Balance 60,234 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. Row 2 · 2026-08-28 · Sale · Disposed 16,010 · Balance 44,224 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F2: This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 3 · 2026-08-28 · Sale · Disposed 6,237 · Balance 37,987 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F3: This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 4 · 2026-08-28 · Sale · Disposed 430 · Balance 37,557 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F4: This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Row 5 · 2026-08-28 · Gift · Disposed 1,000 · Balance 36,557 F5: On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4. |
| Non-Qualifed Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $112.17 · Expires 2030-02-18 | Direct | 0 |
Reported balance
After 2026-08-28 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2026-08-28 · Exercise / conversion · Disposed 22,677 · Balance 0 F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person. F7: The options vested in three equal annual installments beginning on the first annual anniversary of the grant date. |
| Common StockSEC Table I · non-derivative | Indirect401(k)/SDCP | 5,780 |
Reported balance
Holding disclosure · report date 2026-08-28 · row 6
Holding and transaction disclosures are not merged.
1 source rowRow 6 · Balance 5,780 F6: These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date. |
Filing footnotes · ownership attribution and instrument terms
F1: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person.
F2: This transaction was executed in multiple trades at prices ranging from $242.270 to $243.269. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F3: This transaction was executed in multiple trades at prices ranging from $243.270 to $244.225. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F4: This transaction was executed in multiple trades at prices ranging from $244.280 to $245.247. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
F5: On August 28, 2026, the reporting person made a charitable gift of 1,000 shares, a transaction eligible for deferred reporting on Form 5. The reporting person has chosen to report such transaction early on this Form 4.
F6: These underlying shares were acquired on a periodic basis by the trustee of the Company's tax qualified Profit Sharing (401(k)) and/or Supplemental Deferred Compensation Plan. The information was obtained from the plan administrator as of a current date. The number of shares is based on the account balance of the Company stock fund under each Plan (which includes some money market instruments) divided by the market price of the Company's stock as of that date.
F7: The options vested in three equal annual installments beginning on the first annual anniversary of the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 21, 2024 Filed Feb 23, 2024 21:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 407 | $125.02 | $50,883.14 |
DisclosureSEC source: 0001022079-24-000053 · wk-form4_1708724091.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 40,867 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:04 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 12,231 | $0.00 Strike: $127.81 | $0.00 |
DisclosureSEC source: 0001022079-24-000033 · wk-form4_1708131839.xml · derivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 12,231 Underlying: Common Stock · 12,231 shares Expires 2034-02-14 F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 14, 2024 Filed Feb 17, 2024 01:04 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 2,935 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-24-000033 · wk-form4_1708131839.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,274 F1 · security: Represents an award of restricted share units. Read SEC document |
| May 10, 2023 Filed Jan 19, 2024 22:12 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GiftCommon Stock | 188 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-24-000004 · wk-form5_1705702331.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 38,339 F1 · shares: Represents a charitable gift. Read SEC document |
| March 07, 2023 Filed Mar 8, 2023 21:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 4,754 | $140.55 | $668,174.70 |
DisclosureSEC source: 0001022079-23-000070 · wf-form4_167831157762872.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,527 F3 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 27, 2022. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 3,841 | $147.86 | $567,930.26 |
DisclosureSEC source: 0001022079-23-000070 · wf-form4_167831157762872.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,281 F2 · kind: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 06, 2023 Filed Mar 8, 2023 21:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 8,595 | $147.86 | $1,270,856.70 |
DisclosureSEC source: 0001022079-23-000070 · wf-form4_167831157762872.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,122 F1 · kind: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2020, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| March 02, 2023 Filed Mar 3, 2023 21:51 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 593 | $138.54 | $82,154.22 |
DisclosureSEC source: 0001022079-23-000050 · wf-form4_167788026089741.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,527 F2 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 27, 2022. Read SEC document |
| March 01, 2023 Filed Mar 3, 2023 21:51 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 320 | $140.69 | $45,020.80 |
DisclosureSEC source: 0001022079-23-000050 · wf-form4_167788026089741.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,120 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 24, 2023 Filed Feb 27, 2023 21:49 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 1,415 | $141.42 | $200,109.30 |
DisclosureSEC source: 0001022079-23-000035 · wf-form4_167753453710712.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,440 F3 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on May 27, 2022. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:49 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 9,653 | $0.00 Strike: $143.33 | $0.00 |
DisclosureSEC source: 0001022079-23-000035 · wf-form4_167753453710712.xml · derivative · entry 5 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,653 Underlying: Common Stock · 9,653 shares Expires 2033-02-23 F5 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:49 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 2,442 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-23-000035 · wf-form4_167753453710712.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,855 F2 · security: Represents an award of restricted share units. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:49 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 811 | $147.86 | $119,914.46 |
DisclosureSEC source: 0001022079-23-000035 · wf-form4_167753453710712.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,413 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| May 17, 2022 Filed May 19, 2022 20:40 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 50,604 | $66.51 Strike: $66.51 | $3,365,672.04 |
DisclosureSEC source: 0001022079-22-000077 · wf-form4_165299279355521.xml · derivative · entry 4 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 50,604 shares Expires 2026-02-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_date: The options vested in three equal annual installments beginning with the first on February 25, 2017, the second on February 25, 2018 and the final on February 25, 2019. Read SEC document |
| May 17, 2022 Filed May 19, 2022 20:40 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 50,604 | $139.97 | $7,082,991.28 |
DisclosureSEC source: 0001022079-22-000077 · wf-form4_165299279355521.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,224 F1 · price: This transaction was executed in multiple trades at prices ranging from $139.56 to $140.51. The price reported above reflects the weighted average sale price. The reporting person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected. Read SEC document |
| May 17, 2022 Filed May 19, 2022 20:40 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 50,604 | $66.51 | $3,365,672.04 |
DisclosureSEC source: 0001022079-22-000077 · wf-form4_165299279355521.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 89,828 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| March 08, 2022 Filed Mar 9, 2022 21:50 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 6,228 | $135.21 | $842,087.88 |
DisclosureSEC source: 0001022079-22-000060 · wf-form4_164686263665528.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,224 F3 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 31, 2020. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 21:50 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 5,316 | $130.09 | $691,558.44 |
DisclosureSEC source: 0001022079-22-000060 · wf-form4_164686263665528.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,452 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 07, 2022 Filed Mar 9, 2022 21:50 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 11,544 | $130.09 | $1,501,758.96 |
DisclosureSEC source: 0001022079-22-000060 · wf-form4_164686263665528.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,768 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2019, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 21:44 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 661 | $130.00 | $85,930.00 |
DisclosureSEC source: 0001022079-22-000050 · wf-form4_164625742745510.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,224 Read SEC document |
| February 24, 2022 Filed Mar 1, 2022 00:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 13,301 | $0.00 Strike: $127.73 | $0.00 |
DisclosureSEC source: 0001022079-22-000031 · wf-form4_164609488034289.xml · derivative · entry 4 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,301 Underlying: Common Stock · 13,301 shares Expires 2032-02-24 F4 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 24, 2022 Filed Mar 1, 2022 00:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 2,741 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-22-000031 · wf-form4_164609488034289.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,885 F2 · security: Represents an award of restricted share units. Read SEC document |
| February 24, 2022 Filed Mar 1, 2022 00:35 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 1,669 | $126.26 | $210,727.94 |
DisclosureSEC source: 0001022079-22-000031 · wf-form4_164609488034289.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 37,144 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 30, 2020. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 00:13 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 406 | $130.23 | $52,873.38 |
DisclosureSEC source: 0001022079-22-000021 · wf-form4_164583433812398.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 38,813 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| February 23, 2022 Filed Feb 26, 2022 00:13 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 933 | $130.09 | $121,373.97 |
DisclosureSEC source: 0001022079-22-000021 · wf-form4_164583433812398.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,219 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of restricted share units. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionNon-Qualifed Stock Option (right to buy) · Derivative | 44,939 | $71.17 Strike: $71.17 | $3,198,308.63 |
DisclosureSEC source: 0001022079-21-000075 · wf-form4_162041954916213.xml · derivative · entry 4 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 44,939 shares Expires 2025-02-23 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 30, 2020. F3 · derivative.exercise_date: The options vested in three annual installments beginning with the first on February 23, 2016, the second on February 23, 2017 and the final on February 23, 2018. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 44,939 | $137.00 | $6,156,643.00 |
DisclosureSEC source: 0001022079-21-000075 · wf-form4_162041954916213.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,152 F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 30, 2020. Read SEC document |
| May 05, 2021 Filed May 7, 2021 20:32 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 44,939 | $71.17 | $3,198,308.63 |
DisclosureSEC source: 0001022079-21-000075 · wf-form4_162041954916213.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 85,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 30, 2020. Read SEC document |
| March 10, 2021 Filed Mar 11, 2021 21:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 5,574 | $120.47 | $671,499.78 |
DisclosureSEC source: 0001022079-21-000058 · wf-form4_161549827709752.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,152 F3 · kind: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 30, 2021. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 21:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 4,217 | $115.42 | $486,726.14 |
DisclosureSEC source: 0001022079-21-000058 · wf-form4_161549827709752.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,726 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 09, 2021 Filed Mar 11, 2021 21:31 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 9,791 | $115.42 | $1,130,077.22 |
DisclosureSEC source: 0001022079-21-000058 · wf-form4_161549827709752.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,943 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 19, 2018, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:29 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 801 | $115.49 | $92,507.49 |
DisclosureSEC source: 0001022079-21-000046 · wf-form4_161463417669605.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,152 F1 · shares: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on November 30, 2020. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 750 | $116.95 | $87,712.50 |
DisclosureSEC source: 0001022079-21-000043 · wf-form4_161428913031496.xml · nonDerivative · entry 4 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,953 F3 · shares: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on December 1, 2020. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 438 | $116.95 | $51,224.10 |
DisclosureSEC source: 0001022079-21-000043 · wf-form4_161428913031496.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,703 F3 · shares: This sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on December 1, 2020. Read SEC document |
| February 24, 2021 Filed Feb 25, 2021 21:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 455 | $121.19 | $55,141.45 |
DisclosureSEC source: 0001022079-21-000043 · wf-form4_161428913031496.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,141 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 23, 2021 Filed Feb 25, 2021 21:39 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 693 | $121.15 | $83,956.95 |
DisclosureSEC source: 0001022079-21-000043 · wf-form4_161428913031496.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,596 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of previous grants of restricted shares. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:44 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 17,958 | $0.00 Strike: $121.81 | $0.00 |
DisclosureSEC source: 0001022079-21-000023 · wf-form4_161378547899874.xml · derivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,958 Underlying: Common Stock · 17,958 shares Expires 2031-02-17 F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
| February 17, 2021 Filed Feb 20, 2021 01:44 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 3,202 | $0.00 | $0.00 |
DisclosureSEC source: 0001022079-21-000023 · wf-form4_161378547899874.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 43,289 Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 20:45 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionStock Options (Right to Buy) · Derivative | 35,591 | $52.17 Strike: $52.17 | $1,856,604.52 |
DisclosureSEC source: 0001022079-20-000173 · wf-form4_160279473370470.xml · derivative · entry 4 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,591 shares Expires 2024-02-13 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 31, 2020. F2 · derivative.exercise_date: The options vested in three equal annual installments beginning on the first on February 13, 2015, the second on February 13, 2016 and the final on February 13, 2017. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 20:45 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 35,591 | $119.00 | $4,235,329.00 |
DisclosureSEC source: 0001022079-20-000173 · wf-form4_160279473370470.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,087 F2 · kind: The options vested in three equal annual installments beginning on the first on February 13, 2015, the second on February 13, 2016 and the final on February 13, 2017. Read SEC document |
| October 14, 2020 Filed Oct 15, 2020 20:45 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Exercise / conversionCommon Stock | 35,591 | $52.17 | $1,856,604.52 |
DisclosureSEC source: 0001022079-20-000173 · wf-form4_160279473370470.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 75,678 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: This exercise and sale reported were effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on August 31, 2020. Read SEC document |
| March 11, 2020 Filed Mar 12, 2020 21:00 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 2,175 | $104.25 | $226,743.75 |
DisclosureSEC source: 0001022079-20-000077 · wf-form4_158404681478971.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,087 F3 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 24, 2018. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 21:00 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 2,174 | $106.46 | $231,444.04 |
DisclosureSEC source: 0001022079-20-000077 · wf-form4_158404681478971.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,262 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the settlement of said performance share award. Read SEC document |
| March 10, 2020 Filed Mar 12, 2020 21:00 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantCommon Stock | 4,349 | $106.46 | $462,994.54 |
DisclosureSEC source: 0001022079-20-000077 · wf-form4_158404681478971.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 44,436 F1 · shares: Stock issued by Quest Diagnostics Incorporated in settlement of a performance share award dated February 18, 2017, approved in accordance with the requirements of Rule 16b-3(d). Read SEC document |
| February 27, 2020 Filed Feb 28, 2020 22:53 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 690 | $109.02 | $75,223.80 |
DisclosureSEC source: 0001022079-20-000063 · wf-form4_158293036468118.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,087 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 24, 2018. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 22:53 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 668 | $112.90 | $75,417.20 |
DisclosureSEC source: 0001022079-20-000063 · wf-form4_158293036468118.xml · nonDerivative · entry 2 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 40,777 F2 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 26, 2020 Filed Feb 28, 2020 22:53 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | SaleCommon Stock | 321 | $111.09 | $35,659.89 |
DisclosureSEC source: 0001022079-20-000063 · wf-form4_158293036468118.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,445 F1 · kind: The sale reported was effected pursuant to a Rule 10b5-1 sales plan adopted by the reporting person on October 24, 2018. Read SEC document |
| February 25, 2020 Filed Feb 26, 2020 21:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 307 | $113.34 | $34,795.38 |
DisclosureSEC source: 0001022079-20-000047 · wf-form4_158275278608303.xml · nonDerivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,766 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 24, 2020 Filed Feb 26, 2020 21:33 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | Tax withholdingCommon Stock | 382 | $112.17 | $42,848.94 |
DisclosureSEC source: 0001022079-20-000047 · wf-form4_158275278608303.xml · nonDerivative · entry 1 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 42,073 F1 · shares: Disposition of common stock to the issuer solely to cover tax withholding obligations arising from the vesting of a previous grant of restricted shares. Read SEC document |
| February 18, 2020 Filed Feb 21, 2020 01:37 UTC | QUEST DIAGNOSTICS INC DGX · Entity 2118 | GrantNon-Qualifed Stock Option (right to buy) · Derivative | 22,677 | $0.00 Strike: $112.17 | $0.00 |
DisclosureSEC source: 0001022079-20-000031 · wf-form4_158224903048896.xml · derivative · entry 3 PREVOZNIK MICHAEL E · CIK 0001222679 · SVP & General Counsel 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,677 Underlying: Common Stock · 22,677 shares Expires 2030-02-18 F3 · derivative.exercise_date: The options vest in three equal annual installments beginning on the first annual anniversary of the grant date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.